Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02838212
Other study ID # RAM-MORT 2015
Secondary ID
Status Completed
Phase N/A
First received July 13, 2016
Last updated July 15, 2016
Start date February 2016
Est. completion date July 2016

Study information

Verified date July 2016
Source Germans Trias i Pujol Hospital
Contact n/a
Is FDA regulated No
Health authority Spain: Comité Ético de Investigación Clínica
Study type Observational

Clinical Trial Summary

The purpose of this study is to determine the incidence of drug-related deaths in a university hospital during the year 2015


Description:

The investigators aimed to determine the incidence of drug-related mortality of admitted patients in a university hospital during the year 2015


Recruitment information / eligibility

Status Completed
Enrollment 1135
Est. completion date July 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- inpatients deaths and drug-related deaths.

Exclusion Criteria:

- death patients in the emergency room, patients with a death diagnosis not available, and dead patients due to other causes non-drug related.

Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


Intervention

Drug:
adverse drug reaction
drug-related death

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Germans Trias i Pujol Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of drug-related deaths of all hospital admissions during the year 2015 Yes
Secondary Number of drug-related deaths with the suspected drug started the previous week during the year 2015 Yes
Secondary Number of drug-related deaths with drug interactions between suspected drugs during the year 2015 Yes
Secondary Number of preventable drug-related deaths assessed by Schumock criteria during the year 2015 Yes
Secondary Number of drug-related deaths with polypharmacy Polypharmacy: when patient received >10 drugs during the year 2015 Yes
Secondary Number of drug-related deaths with autopsy during the year 2015 Yes
Secondary Number of drug-related deaths in which the suspected drug had a contributive role during the year 2015 Yes
Secondary Number of drug-related deaths with "certain" or "probable" categories assessed by World Health Organization (WHO) criteria and Naranjo algorithm during the year 2015 Yes
Secondary Number of drug-related deaths presented during hospitalization during the year 2015 Yes
Secondary Risk factors of drug-related deaths risk factors assessed: age, sex, Charlson score, and hospitalization length during the year 2015 Yes
Secondary Incidence of drug-related deaths of all inpatients deaths during the year 2015. Yes
See also
  Status Clinical Trial Phase
Suspended NCT02559960 - Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
Completed NCT01946919 - Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study
Recruiting NCT04154553 - Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure
Completed NCT01732302 - Educational Intervention to Reduce Drug-related Hospitalizations in Elderly Primary Health Care Patients N/A
Completed NCT05224804 - Pharmacists' Knowledge and Attitudes About ADRs Reporting and Pharmacovigilance Practice in Egyptian Hospitals
Completed NCT02297126 - A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program N/A
Completed NCT03093818 - PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions N/A
Not yet recruiting NCT04568668 - Evaluating ActionADE in Reducing Adverse Drug Reactions N/A
Recruiting NCT02012504 - Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients Phase 0
Completed NCT01872520 - Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan A Real World Study N/A
Completed NCT01467050 - Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients Phase 4
Completed NCT01679964 - Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study Phase 4
Completed NCT02094638 - Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study N/A
Recruiting NCT01906710 - the Pharmacy Intervention Team Hospital-based (PITH) for People Study: Effect on Clinical and Economic Outcomes N/A
Completed NCT02888834 - Serious Adverse Drug Reaction and Their Preventability N/A
Completed NCT02159209 - The Drug Induced Renal Injury Consortium N/A
Completed NCT02134587 - Educational Intervention in Pharmacovigilance for Hospital Health Professionals N/A
Completed NCT04553107 - Reducing Costs by Deprescribing Medications N/A
Recruiting NCT06219720 - The Texas Interprofessional Pharmacogenomics (IPGx)
Recruiting NCT05508763 - Personalised Therapeutics @LUMC